Evaluation of a novel photosensitizing drug having antitumor effect for advanced prostate cancer

Sachiko Saito; Mizuho Inai; Norihiro Honda; Hisanao Hazama; Yasufumi Kaneda; Kunio Awazu

doi:10.1117/12.2286071

1 August 2017 Evaluation of a novel photosensitizing drug having antitumor effect for advanced prostate cancer

Sachiko Saito, Mizuho Inai, Norihiro Honda, Hisanao Hazama, Yasufumi Kaneda, Kunio Awazu

Proceedings Volume 10417, Medical Laser Applications and Laser-Tissue Interactions VIII; 1041705 (2017) https://doi.org/10.1117/12.2286071
Event: European Conferences on Biomedical Optics, 2017, Munich, Germany

Abstract

Prostate cancer is the second most frequently diagnosed cancer among men worldwide and a novel treatment for the disease is required. Replication-deficient virus particles, hemagglutinating virus of Japan envelope (HVJ-E), has cytotoxicity to cancer cells. To enhance the therapeutic effect of HVJ-E by photodynamic therapy (PDT) as a trigger of HVJ-E’s anti-tumor effect, talaporfin sodium (Laserphyrin) used for PDT was encapsulated into HVJ-E to produce a novel photosensitizing drug, named Laserphyrin ®-HVJ-E, and its therapeutic effect for prostate cancer cells (PC-3) was evaluated. As the results, direct cytotoxicities of HVJ-E and Laserphyrin ®-HVJ-E for PC-3 after an administration time of 48 h were almost the same. Cell survival rates of PC-3, which were irradiated 2 h after administration of Laserphyrin ®-HVJ-E, were about 7.8%. Although further study is needed to find an optimal PDT condition, these results suggest that Laserphyrin ®-HVJ-E is useful for treatment of prostate cancer due to the combination of cytotoxicities of HVJ-E and PDT.

Citation Download Citation

Sachiko Saito, Mizuho Inai, Norihiro Honda, Hisanao Hazama, Yasufumi Kaneda, and Kunio Awazu "Evaluation of a novel photosensitizing drug having antitumor effect for advanced prostate cancer", Proc. SPIE 10417, Medical Laser Applications and Laser-Tissue Interactions VIII, 1041705 (1 August 2017); https://doi.org/10.1117/12.2286071

ACCESS THE FULL ARTICLE

INSTITUTIONAL
Select your institution to access the SPIE Digital Library.

SELECT YOUR INSTITUTION

PERSONAL
Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.

PERSONAL SIGN IN

No SPIE Account? Create one

PURCHASE THIS CONTENT

SUBSCRIBE TO DIGITAL LIBRARY

50 downloads per 1-year subscription

Members: $195

Non-members: $335 ADD TO CART

25 downloads per 1 - year subscription

Members: $145

Non-members: $250 ADD TO CART

PURCHASE SINGLE ARTICLE

Includes PDF, HTML & Video, when available